Treatment Experienced GT3 patient with Cirrhosis - Geoffrey McCaughan, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Is Treatment Cost-effective? - Kosh Agarwal, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? - Xavier Forns, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

When to Treat HCV in a Waiting List Patient? - Stefano Fagiuoli, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Achieving SVR in CTP C – MELD Purgatory - Christophe Duvoux, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? - Maria Londoño, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Use of HCV+ Donor Grafts - Didier Samuel, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Post-LT Renal Failure and HCV Rx - Peter Ferenci, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Obstacles to Treatment: Renal Disease, Ribavirin, DDIs - Michael Charlton, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Abstract: Does hepatitis D in HBV/ HIV co-infected patients affect liver function? | J. Kozlowska #1

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Abstract: Antioxidant response in patients with chronic hepatitis B or C. | K. Wójcik-Cichy #2

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

State of the Art Treatment of Hepatitis B | Maria Buti, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Abstract: Chronic Hepatitis C Treatment In Patients Coinfected With HCV/HIV | S. Fedorchenko #4

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Abstract: Toll-like receptor 4 polymorphism influence on the clinical course of chronic hepatitis C in HIV-infected patients | T. Kyrychenko #5

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Acute Hepatitis C Infection | Christoph Boesecke, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Abstract: Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1. | S. Mauss #6

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Abstract: Endothelial dysfunction and its influence on the development of subclinical atherosclerosis in HIV/HCV positive patients | K. Barska #10

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Abstract: Evaluation of early cerebral alterations in the course of HIV and HCV infection using perfusion MR imaging: is the hepatitis C virus more dangerous for the brain? | J. Bladowska #8

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Poland | Milosz Parczewski, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

AbbVie

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Ukraine | Larisa Moroz, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Romania | Adrian Streinu Cercel, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Baltic Countries | Saulius Caplinskas, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Local Situation in Czech and Slovak Republics | Viktor Aster, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015